Nutex Health (NUTX) CLO acquires shares and corrects RSU holdings
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Nutex Health Inc. Chief Legal Officer-Healthcare Pamela W. Montgomery reported acquiring additional equity in the company. She made an open-market purchase of 79 shares of common stock at a price of $88.8699 per share, bringing her directly held common stock position to 2,758 shares.
She also exercised a derivative position in the form of 1,523 restricted stock units, converting them into an equivalent common stock interest at a stated exercise price of $0.00, with 4,441 restricted stock units beneficially owned following this transaction. A footnote explains that this filing corrects the previously reported number of restricted stock units from an earlier Form 4 relating to the March 10, 2026 RSU grant.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 79 shares ($7,021)
Net Buy
2 txns
Insider
Montgomery Pamela W.
Role
Chief Legal Officer-Healthcare
Bought
79 shs ($7K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 79 | $88.8699 | $7K |
| Exercise | Restricted Stock Unit | 1,523 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 2,758 shares (Direct);
Restricted Stock Unit — 4,441 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What insider transactions did Nutex Health (NUTX) report for Pamela W. Montgomery?
Pamela W. Montgomery reported two acquisition-side transactions. She bought 79 shares of Nutex Health common stock in the open market and exercised 1,523 restricted stock units, increasing both her direct shareholdings and her restricted stock unit position in the company.
What happened with Pamela W. Montgomery’s restricted stock units in Nutex Health (NUTX)?
She exercised 1,523 restricted stock units tied to Nutex Health common stock. Following this derivative exercise, the filing states she beneficially owns 4,441 restricted stock units, and clarifies that this Form 4 corrects the previously reported RSU balance from an earlier filing.
Was Pamela W. Montgomery’s Nutex Health (NUTX) Form 4 a correction?
Yes, the Form 4 includes a corrective element. A footnote states that it corrects the number of restricted stock units beneficially owned after the RSU grant reported in her earlier Form 4 filed on March 10, 2026, for a March 10, 2026 transaction.
What prices are associated with Pamela W. Montgomery’s Nutex Health (NUTX) transactions?
The open-market purchase was at $88.8699 per common share. The derivative transaction involved exercising 1,523 restricted stock units at an exercise price of $0.00 per unit, converting them into an equivalent interest in Nutex Health common stock.